by admin | March 1, 2013 6:59 am
March 1, 2013—The Office of Pharmacy Affairs (OPA) and Apexus/340B Prime Vendor Program (PVP) have each issued lengthy FAQs fleshing out OPA’s new interpretation of the 340B statute’s “GPO prohibition.”
The 340B law prohibits disproportionate share (DSH), children’s, and free-standing cancer hospitals from participating in group purchasing organizations for 340B drugs, which are for outpatients only.[ms-protect-content id=”2799″]
OPA had offered limited guidance on the GPO exclusion’s parameters until Feb. 7, when it issued a policy release[1] invalidating drug-replenishment systems that use GPOs to make initial purchases of drugs and subsequently replace them with 340B-purchased drugs. It gave affected hospitals until April 7 to comply with the drug-replenishment requirements in the new policy. Hospitals that violate the prohibition will be removed from the 340B program, including all of their enrolled outpatient sites and contract pharmacies, OPA said. They might also be required to repay manufacturers. To be considered for reinstatement, they would first have to demonstrate their ability to comply with the requirement.
In its FAQ, OPA said a hospital had the following options if it cannot meet the April 7 deadline.
The OPA FAQ[2] has 19 questions and answers and the PVP version[3] has 40. PVP also issued a document[4] entitled “340B GPO Prohibition and Wholesaler WAC Account Load Options” that it said is intended “to facilitate 340B compliance in the marketplace.”[/ms-protect-content]
Source URL: https://340bemployed.org/two-new-faqs-on-340b-group-purchasing-prohibition/
Copyright ©2025 340bemployed.org unless otherwise noted.